Vaxart Names Grasman as CFO, Succeeding Lee

Dow Jones

May 14, 2025

By Connor Hart

Vaxart appointed Jeroen Grasman as its chief financial officer, effective May 19.

Grasman will succeed Phillip Lee, who is resigning from the top finance position for personal reasons, the clinical-stage biotechnology company said Tuesday.

Lee will remain with the company as a non-executive employee through June 1 in order to assist with the transition.

Grasman has more than 20 years of financial leadership experience in the biotechnology industry, Vaxart said. He most recently served as CFO of AltruBio, a private clinical-stage biotech company. Prior, he held leadership roles at PACT Pharma and Intarcia Therapeutics.

Vaxart disclosed the CFO succession as it posted a net loss of $15.6 million, or 7 cents a share in the first quarter, compared with a loss of $24.4 million, or 14 cents a share, a year earlier.

Revenue increased to $20.9 million from $2.2 million.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

May 13, 2025 16:21 ET (20:21 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2535082336"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535082336\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535082336?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 04:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535082336","market":"us","top_or_hot":-1,"title":"Vaxart Names Grasman as CFO, Succeeding Lee","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<p>\n  Vaxart appointed Jeroen Grasman as its chief financial officer, effective May 19. \n</p>\n<p>\n  Grasman will succeed Phillip Lee, who is resigning from the top finance position for personal reasons, the clinical-stage biotechnology company said Tuesday. \n</p>\n<p>\n  Lee will remain with the company as a non-executive employee through June 1 in order to assist with the transition. \n</p>\n<p>\n  Grasman has more than 20 years of financial leadership experience in the biotechnology industry, Vaxart said. He most recently served as CFO of AltruBio, a private clinical-stage biotech company. Prior, he held leadership roles at PACT Pharma and Intarcia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. \n</p>\n<p>\n  Vaxart disclosed the CFO succession as it posted a net loss of $15.6 million, or 7 cents a share in the first quarter, compared with a loss of $24.4 million, or 14 cents a share, a year earlier. \n</p>\n<p>\n  Revenue increased to $20.9 million from $2.2 million. \n</p>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 13, 2025 16:21 ET (20:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart Names Grasman as CFO, Succeeding Lee</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart Names Grasman as CFO, Succeeding Lee\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-14 04:21</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Connor Hart \n</p>\n<p>\n  Vaxart appointed Jeroen Grasman as its chief financial officer, effective May 19. \n</p>\n<p>\n  Grasman will succeed Phillip Lee, who is resigning from the top finance position for personal reasons, the clinical-stage biotechnology company said Tuesday. \n</p>\n<p>\n  Lee will remain with the company as a non-executive employee through June 1 in order to assist with the transition. \n</p>\n<p>\n  Grasman has more than 20 years of financial leadership experience in the biotechnology industry, Vaxart said. He most recently served as CFO of AltruBio, a private clinical-stage biotech company. Prior, he held leadership roles at PACT Pharma and Intarcia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. \n</p>\n<p>\n  Vaxart disclosed the CFO succession as it posted a net loss of $15.6 million, or 7 cents a share in the first quarter, compared with a loss of $24.4 million, or 14 cents a share, a year earlier. \n</p>\n<p>\n  Revenue increased to $20.9 million from $2.2 million. \n</p>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 13, 2025 16:21 ET (20:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2535082336","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535082336","pubTimestamp":1747167660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Vaxart appointed Jeroen Grasman as its chief financial officer, effective May 19.Grasman will succeed Phillip Lee, who is resigning from the top finance position for personal reasons, the clinical-stage biotechnology company said Tuesday.Lee will remain with the company as a non-executive employee through June 1 in order to assist with the transition.Grasman has more than 20 years of financial leadership experience in the biotechnology industry, Vaxart said. He most recently served as CFO of AltruBio, a private clinical-stage biotech company. Prior, he held leadership roles at PACT Pharma and Intarcia Therapeutics.Vaxart disclosed the CFO succession as it posted a net loss of $15.6 million, or 7 cents a share in the first quarter, compared with a loss of $24.4 million, or 14 cents a share, a year earlier.Revenue increased to $20.9 million from $2.2 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VXRT":"Vaxart, Inc.","BK4568":"美国抗疫概念"},"translate_title":"Vaxart任命Grasman接替Lee担任首席财务官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXRT":0.9},"content_text":"By Connor Hart \n\n\n  Vaxart appointed Jeroen Grasman as its chief financial officer, effective May 19. \n\n\n  Grasman will succeed Phillip Lee, who is resigning from the top finance position for personal reasons, the clinical-stage biotechnology company said Tuesday. \n\n\n  Lee will remain with the company as a non-executive employee through June 1 in order to assist with the transition. \n\n\n  Grasman has more than 20 years of financial leadership experience in the biotechnology industry, Vaxart said. He most recently served as CFO of AltruBio, a private clinical-stage biotech company. Prior, he held leadership roles at PACT Pharma and Intarcia Therapeutics. \n\n\n  Vaxart disclosed the CFO succession as it posted a net loss of $15.6 million, or 7 cents a share in the first quarter, compared with a loss of $24.4 million, or 14 cents a share, a year earlier. \n\n\n  Revenue increased to $20.9 million from $2.2 million. \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2025 16:21 ET (20:21 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}